scholarly journals COVID19 infection revealed chronic myeloid leukemia in chronic phase: A case report

2020 ◽  
pp. 149
Author(s):  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase

scholarly journals Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report

2021 ◽  
pp. 225
Author(s):  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Symptomatic Treatment ◽  
Molecular Response ◽  
Toxicity Profile ◽  
Efficacy And Safety ◽  
Major Molecular Response

Treatment for Chronic myeloid leukemia has been revolutionized because of availability of different tyrosine kinase inhibitors. Each TKI come with its on toxicity profile as this needs to be taken in account before starting therapy with particular agent in a patient. Most of the adverse effects related to TKI are mild and can be managed by either symptomatic treatment or either by dose reduction. But some patients can become intolerant and to switch to other TKI remains the only option. Bosutinib is currently approved for treatment of chronic phase CML in patients who are either resistant or intolerant to previous TKI. We present a case of 59 year old male patient with CML who was intolerant to Dastanib and Nilotinib but showed excellent hematological and major molecular response to bosutinib

A case report of a 33-year chronic phase survivor of chronic myeloid leukemia

2011 ◽  
Vol 29 (2) ◽  
pp. 1102-1104
Author(s):  
Ou Ji ◽  
Qun Shen ◽  
Ya-Cheng Zhang ◽  
Jian-Min Ji ◽  
Guang-Rong Zhu ◽  
...  
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase

scholarly journals Efficacy and safety of Bosutinib in Patient with Chronic myeloid leukemia who was intolerant to DASTANIB,NILOTUNIB -Case report

2021 ◽  
Author(s):  
Abdullah Mohammad Arshad ◽  
mohamed yassin
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Molecular Response ◽  
Efficacy And Safety ◽  
Major Molecular Response ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

Bosutinib is approved as first line therapy for treatment of chronic phase CML and also in patients who are either resistant or intolerant to previous TKI. We present a 59 year old male who was intolerant to 2 TKI but showed excellent hematological and major molecular response to Bosutinib.

scholarly journals Management of Chronic Myeloid Leukemia with Sever COVID 19: A Case Report

2020 ◽  
Vol 8 (T1) ◽  
pp. 304-308
Author(s):  
Rasha Ibrahim ◽  
Georgios P. Chatzis ◽  
Mohamed A. Korayem ◽  
Mahmoud K. Mansour
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Respiratory Distress Syndrome ◽  
Myeloid Leukemia ◽  
Hematological Malignancies ◽  
Distress Syndrome ◽  
Chronic Phase ◽  
Viral Disease ◽  
Acute Respiratory Disease

Coronavirus disease-19 (COVID-19) is a pandemic viral disease that can cause devastating complications such as acute respiratory disease, especially in patients with comorbidities. We do not know yet full pictures of this disease, especially in hematological malignancies. Here, we present management of a 57-year-old male with chronic phase chronic myeloid leukemia, tested positive for COVID-19, then complicated with acute respiratory distress syndrome.

Sign in / Sign up

Export Citation Format

Share Document